Format

Send to

Choose Destination
See comment in PubMed Commons below
Lung Cancer. 2014 Nov;86(2):170-3. doi: 10.1016/j.lungcan.2014.08.016. Epub 2014 Aug 29.

Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).

Author information

1
Service de pneumologie APHP, Saint Antoine, Paris, France.
2
CH Le Chesnay, France.
3
CAC, Caen, France.
4
CHI Creteil, France.
5
CAC Marseille, France.
6
CH Draguignan, France.
7
CH Mantes la Jolie, France.
8
HIA Toulon, France.
9
CH Gap, France.
10
CHU Rennes, France.
11
CHU Brest, France.
12
CHU Angers, France.
13
CH La Roche sur Yon, France.
14
CH Cercy Pontoise, France.
15
CH Meaux, France.
16
CH Aix en Provence, France.
17
CH Annecy-Genevois, Pringy, France.
18
CHU Limoges, France. Electronic address: alain.vergnenegre@unilim.fr.

Abstract

OBJECTIVES:

When advanced non-small-cell lung cancer (NSCLC) progresses during first-line treatment, re-biopsy may be indicated to detect a possible new biological profile (comparison to initial status, emergence of resistance biomarkers, or assessment of new biomarkers). The aim of this pragmatic prospective multicenter study was to assess the feasibility and clinical utility of re-biopsy in advanced NSCLC in a real-world setting.

METHODS:

The main inclusion criteria were advanced NSCLC with an indication for repeat biopsy identified by the patient's clinician. The primary outcome was the percentage of successful procedures. Secondary outcomes were the type of procedure, new biological status, tolerability of the procedure, and clinical utility (treatment modification).

RESULTS:

From May 2012 to May 2013, 18 centers enrolled 100 patients (males: 44%; median age: 64.8 years; PS 0/1: 88%; adenocarcinoma: 89%; EGFR mutated: 50%; no initial biological profile: 16.4%). Re-biopsy was not possible in 19.5% of cases and provided no or too few tumor cells in 25.6% of cases. Repeat biopsy was useful for guiding treatment in 30.4% (25/82) of cases. Complications were infrequent (2 cases of moderate bleeding and 1 case of pneumothorax).

CONCLUSION:

Re-biopsy of advanced NSCLC is feasible in the real-world setting, with acceptable adverse events. Guidelines are needed on the indications of re-biopsy, the choice of procedure, the sampling site, and laboratory analysis.

KEYWORDS:

Biomarkers; Clinical management; Guidelines; Non small cell lung cancer; Re-biopsy

PMID:
25214431
DOI:
10.1016/j.lungcan.2014.08.016
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center